Antineoplastic Effect of PAC Capped Silver Nanoparticles Promote Apoptosis in HT-29 Human Colon Cancer Cells
- 11 Downloads
Proanthocyanidin (PAC) is an anti-cancer drug that effectively treat various cancers, including colon cancer. Whereas, the chemotherapeutic potential has restricted to low bioavailability and more defects. To overcome these complications, PAC produces a selective intend of AgNPs as a medicine for cancer cells and growing modern antineoplastic promoter, an innovative nano-capped drug was enhanced bioavailability of tumor cells. The synthesized PAC-AgNPs was described by spectroscopy analysis. Phenolic compound has hydroxyl groups which are able to bind to metals and reduce the metal salt and provide stability against agglomeration was confirmed by FTIR and spherical or polygonal shape with an average size of 72.35 nm found through FE-SEM analysis, applicable for targeted delivery to specific tissues. The potential of this nano-incorporate drug had been caused apoptosis in colon cancer cells was measured. Significantly, it was found in decreasing cell growth by MTT assay, morphological changes such as membrane blebbing and chromatin condensation exhibited in AO/EB staining. At the end, the mitochondrial pathway of apoptotic cell death confirmed by cell cycle progression as well as annexin V/PI. These results strongly suggest that PAC-AgNPs could be used as a major nano-composite therapeutic drug for effectively treated with colon cancer.
KeywordsPAC-AgNPs MTT AO/EB staining Cell cycle arrest Annexin V/FITC
The authors gratefully acknowledge the DST-INSPIRE sponsored program, Department of Science and Technology, New Delhi (REF. NO: DST/INSPIRE Fellowship/2015/IF150459). We also acknowledge Head, Department of Biotechnology, K. S. Rangasamy College of Technology for the support offered towards the study. The authors also acknowledge DST-FIST (fund for infrastructure for science and technology) FIST NO: 368 for the support given carry out the study.
- 6.D. A. Gewirtz, M. L. Bristol, and J. C. Yalowich (2010). Curr. Opin. Investig. Drugs 11, 612.Google Scholar
- 25.S. Gurunathan, J. W. Han, V. Eppakayala, M. Jeyaraj, and J. H. Kim (2013). Biomed. Res. Int. 53, 5796.Google Scholar
- 26.S. N. Ostad, S. Dehnad, Z. E. Nazari, S. T. Fini, N. Mokhtari, M. Shakibaie, and A. R. Shahverdi (2010). Avicenna J. Med. Biotechnol. 2, 187.Google Scholar
- 30.P. K. Manga Veni, G. Devendra Vijaya, P. Durga, and P. S. Bhushanavathi (2017). J. Chem. Pharm. Sci. 10, 583.Google Scholar
- 39.S. R. Senthilkumar and T. Sivakumar (2014). Int. J. Pharm. Pharm. Sci. 6, 461.Google Scholar
- 43.N. Karthi and V. Manju (2014). Indian J. Res. Pharm. Biotechnol. 2, 1246.Google Scholar
- 47.M. A. Navo, J. A. Smith, A. Gaikwad, T. Burke, J. Brown, and L. M. Ramondetta (2008). Pharmacology 62, 483.Google Scholar